Home' Australian Pharmacist : Australian Pharmacist February 2012 Contents Australian Pharmacist February 2012 I ©Pharmaceutical Society of Australia Ltd. 159
Cozavan® (losartan potassium) is PBS listed for RRMS1
Alphapharm recently announced the reintroduction on to the PBS of the first AIIRA oral anti-
hypertensive1 losartan potassium under the brand name Cozavan2.
Losartan potassium is a well-established AIIRA treatment for hypertension globally3, 4, 5, originally
brought to the market 13 years ago as Cozaar® by MSD.
Cozavan® (losartan potassium) is indicated for the treatment of hypertension and to delay
the progression of renal disease in hypertensive type 2 diabetics with proteinuria1.
At a starting dose of 50mg daily1 for most patients Cozavan® is available at a dispensed price
for maximum quantity of $27.84 for 60 tabs (2 packs of 30s) for 50mg as well as $13.92 for 30 tablets
of 25 mg2.
1. COZAVAN® Approved Product Information, date of most recent amendment 12 July 2010.
2. Pharmaceutical Benefits Scheme, 1 December 2011 accessed 13/12/2011 at www.pbs.gov.au/medicine/item/8203R
3. IMS, All Countries Angiotensin II Receptor Antagonist data, 2008--2010.
4. Heran BS, et al. Cochrane Database Syst Rev 2008;Oct8(4):CD 003823.
5. Willenheimer et al. Eur Heart J 1999; 20:997--1008
PBS Information: General Benefit.
Please review full Product Information before prescribing.
Full Product Information is available on request from Alphapharm Pty Ltd.
Merck Sharp & Dohme
Zoely (nomegestrol acetate/oestradiol),
a new combined oral contraceptive
(COC) made from a combination of
hormones similar to a woman's own
has been approved by the Therapeutic
Goods Administration (TGA).1
Zoely is made of a highly-selective
progestogen (nomegestrol acetate --
NOMAC) derived from progesterone
and an oestrogen (17beta-oestradiol
-- E2) that is structurally identical to
endogenous oestrogen produced
naturally in a woman's body.1 Through
synergistic effects of NOMAC and E2,
Zoely delivers >99% contraceptive
efficacy, short, light and less painful
withdrawal bleeds compared to
ethinyloestradiol and drospirenone,
with a neutral effect on acne and
weight for most patients.2 It is offered
in a 24/4 monophasic regimen.1,3
It is not PBS listed.
Sexual Health Physician, Dr Terri
Foran, said that Zoely is a welcome
addition to the range of combined oral
contraceptive pills presently available
in Australia. 'The advent of oestradiol-
containing pills in the past few years
has provided yet another choice for
women who opt for oral contraception
and Zoely has the advantage of easy-
to-follow packaging. Not only does the
combination of NOMAC and oestradiol
provide effective contraception but the
very light periods experienced by most
women using it will probably appeal
The efficacy, tolerability and safety of
Zoely has been studied in seven multi-
centre clinical trials across Europe, Asia,
and Australia. The trials involved more
than 3,400 women, aged between 18
and 50 years, who completed more
than 35,000 cycles.1 Key findings from
the clinical trials showed:
• Zoely was well tolerated and had a
safety profile that was similar to other
• Over 99% efficacy, with
effectiveness in inhibiting ovulation,
as demonstrated by the inhibition
of follicular growth.3
• Of women taking Zoely, 90%
experienced improvement (16%) or no
change (74%) in acne.3
• Over 90% of women taking Zoely did
not report an increase in weight.1
• Withdrawal bleeds were shorter
(on average 3--4 days), lighter and less
painful compared to COC containing
ethinyloestradiol and drospirenone1.2,3
• Women using Zoely experienced
overall a low number of
• NOMAC has a 46 hour half-life.1
1 Zoely Product Information. Approved Aug 2011
2 Australian Public Assessment Reports for prescription
medicines (AusPARs).Australian Public Assessment Report
for Nomegestrol acetate/Oestradiol, Oct 2011. (Cited Dec
2011). At: www.tga.gov.au/pdf/auspar/auspar-zoely.pdf
3 Mansour D, et al. Eur J Contracept Reprod Health Care.
Links Archive Australian Pharmacist March 2012 Australian Pharmacist January 2012 Navigation Previous Page Next Page